MYGN250516P22000
- 0.00
- 0.000.00%
Myriad Genetics Newsroom
Express News | Myriad Genetics Inc Outlook FY 2025 Rev $807 Mln - $823 Mln
Express News | Myriad Genetics Lowers FY2025 Adj EPS Guidance From $0.07-$0.11 to $(0.02)-$0.02 Vs $0.08 Est; Lowers FY2025 Sales Guidance From $840.00M-$860.00M to $807.00M-$823.00M Vs $844.87M Est
Myriad Genetics | 8-K: Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
Earnings Flash (MYGN) Myriad Genetics Posts Q1 Adjusted EPS $-0.03, Vs. FactSet Est of $-0.05
Express News | Myriad Genetics Q1 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $195.90M Miss $200.56M Estimate
Express News | Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
Express News | Myriad Genetics Q1 Operating Expenses USD 163.2 Million
Express News | Myriad Genetics Q1 Gross Margin 69%
Myriad Genetics 1Q Rev $195.9M >MYGN
Press Release: Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
Myriad Genetics Q1 25 Earnings Conference Call At 4:30 PM ET
Here Are the Major Earnings After the Close Today
Earnings Scheduled For May 6, 2025
Craig-Hallum Maintains Myriad Genetics(MYGN.US) With Buy Rating
Myriad Genetics's Earnings: A Preview
Earnings Preview: MYGN to Report Financial Results Post-market on May 06
Myriad Genetics Announces Survey Results on Depression, Anxiety
Concerns About Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed With Depression and Anxiety, According to the GeneSight Mental Health Monitor
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Express News | Myriad Genetics To Present At AACR Annual Meeting On Apr. 28